Mr. Kempen joined Gossamer Bio in March 2018 and played a key role in building the Clinical Operations department and leading operations for multiple clinical development programs. He has served as Head of Global Clinical Operations since March 2022. Mr. Kempen has over 23 years of experience in biopharma clinical operations, across all phases of development, with a strong focus on late phase registrational programs including ozanimod (Zeposia) in multiple sclerosis and inflammatory bowel disease, and lesinurad (Zurampic) in hyperuricemia and gout.

Prior to joining Gossamer Bio, Mr. Kempen was responsible for leading Clinical Operations at Receptos (Celgene) from 2015-2018 and led clinical operations at Ardea Biosicences (a wholly owned subsidiary of AstraZeneca) from 2011-2015. Prior to 2011 Mr. Kempen held various roles of increasing leadership responsibility at Allergan Pharmaceuticals and PPD, after starting his career as a CRA at ICON, plc. Mr. Kempen holds a B.S. in Health Information Management as well as a M.S. in Drug Development and Product Management.